Clinical Trials Logo

Metastatic Colo-rectal Cancer clinical trials

View clinical trials related to Metastatic Colo-rectal Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01358812 Completed - Clinical trials for Metastatic Colo-rectal Cancer

FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer

TRIP
Start date: March 2010
Phase: Phase 2
Study type: Interventional

The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy compared to FOLFIRI in a phase III trial. Panitumumab with oxaliplatin- or irinotecan-based doublets is feasible and associated with improved activity in KRAS codon 12-13 wild-type patients. BRAF and other RAS rare mutations have been suggested as additional potential biomarkers for anti-EGFR agents in metastatic colo-rectal cancer. The present study aims to demonstrate the feasibility and the activity of the first-line combination of the GONO-FOLFOXIRI regimen and Panitumumab in molecularly selected metastatic colo-rectal cancer patients.